Intalight Receives CE Mark for its DREAM OCT Platform

Intalight announced it has received CE mark for its DREAM OCT platform, the newest version of optical coherence tomography (OCT). The CE mark serves as approval by the European Union for commercialization of the platform. 

“Intalight is incredibly proud to receive CE mark approval in Europe for our DREAM OCT,” Shawn Peng, Intalight chairman and Founder, said in a recent press release. “This achievement allows us to provide ophthalmologists in Europe with state-of-the-art technology that delivers improved results for their patients.” 

DREAM stands for: "Deep imaging depth, Rapid sweeping speed, Extensive scan range, Accurate results, and Multimodal imaging capabilities." It covers an ultrawide field single scan and delivers a 130° OCTA image. According to the company, the swept source OCT’s 12 mm super-depth scanning allows superior imaging of the choroid and retina and a large portion of the vitreous space. It also scans 16.2 mm (in air) anteriorly, allowing for the complete anterior segment from the cornea to the anterior part of the vitreous to be seen in only one scan.

“Over the past few years, we’ve heard from eye care professionals that they need a solution that gets them over the imaging finish line with speed, accuracy and depth,” said Bing Li, Intalight CEO and Co-Founder. “DREAM OCT delivers a full set of imaging modalities for the most challenging clinical and research applications for the retina and outperforms everything else HCP’s know.”

The company states this platform offers the highest quality images available on the market. More than 160 peer-reviewed papers have utilized findings from DREAM OCT devices. 

Intalight currently collaborates with the top retina academic institutions and retina private practices in the United States, Europe, and Asia, with plans to make this technology available in the US as soon as possible.